P. Astoul (Marseille Cedex 09, France), N. Dickgreber (Hannover, Germany)
Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients
J. Skrickova, M. Tomiskova, I. Vasutova, B. Kadlec, J. Kaplanova, L. Babickova, P. Turcani, T. Nebesky, L. Kren, L. Buresova (Brno, Czech Republic)
|   |
Granulocyte colony-stimulating factor enhances the anticancer effects of cisplatin against lung cancer by promoting angiogenesis
J. Endo, Y. Ohno, F. Ito, H. Mori, N. Funaguchi, B. L. Bai La, K. Gotoh, S. Minatoguchi (Gifu, Japan)
| |
Systemic inflamatory reaction following pleurodesis with talk surray
M. Lerikou, G. Antoniou, D. Hajhilia, M. Zontanos, G. Pavlakou, P. Demertzis, O. Anagnostopoulou (Athens, Greece)
| |
A phase II trial of lipoplatin-gemcitabine in patients with advanced NSCLC: preliminary results
S. Anevlavis, A. Pataka, G. Kouliatsis, S. Pozova, P. Steiropoulos, D. Bouros, M. Froudarakis (Alexandroupolis, Greece)
| |
Clinical characteristic of lung cancer patients with interstitial pneumonia treated with chemotherapy or radiotherapy
T. Kinoshita, K. Azuma, M. Okamoto, M. Nakao, N. Edakuni, J. Ikeda, T. Hoshino, T. Iwanaga, H. Aizawa (Kurume, Fukuoka, Japan)
| |
Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice
M. Faehling, S. Kuom, M. Leschke, M. Geissler, T. Kamp, R. Eckert (Esslingen, Wendlingen, Germany)
| |
Mutations of EGFR and k-ras genes and TK inhibitors. Are there differences between gefitinib and erlotinib?
M. Pesek, L. Benesova, F. Bruha, B. Belsanova, P. Mukensnabl, T. Vanecek, M. Minarik (Plzen, Praha, Czech Republic)
| |
Prophylactic cranial irradiation in small-cell lung cancer patients
N. Secen, D. Bursac, M. Kakas, D. Sazdanic-Velikic, V. Canak (Sremska Kamenica, Serbia And Montenegro)
| |
Topotecan in combination with carboplatin and etoposide as first line treatment in SCLC patients: a phase I/II study – final results
K. Zarogoulidis, E. Mylonaki, P. Kakavelas, A. Rapti, T. Tsiouda, P. Christaki, P. Zarogoulidis, T. Kontakiotis (Exochi Thessaloniki, Athens, Greece)
| |
Timing of radiotherapy and possible survival benefit in limited disease SCLC patients
K. Zarogoulidis, N. Secen, E. Boutsikou, A. Milovancev, E. Eleutheriadou, D. Bursac, V. Zarogoulidou, D. Skrbic, H. Lithoxopoulou, T. Kontakiotis (Sremska, Kamenica, Serbia And Montenegro; G. Papanikolaou Hospital, Greece)
| |
Phase II open-label trial of erlotinib in progressive pretreated advanced non-small cell lung cancer (NSCLC)
F. Piantedosi, M. Gilli, F. Caputo, B. Casale, A. Pontillo, S. A. Marsico, A. Bianco (Napoli, Campobasso, Italy)
| |
Study on coagulation abnormality and effect of anticoagulation on prognosis in advanced cases of non-small cell lung cancer
Y. Zhang, H. Dai, C. Wang (Beijing, China)
| |
Targeting neuropeptide receptors by substance-P analogues identifies a strategy to develop novel anti-cancer therapies
A. MacKinnon, T. Sethi (Edinburgh, United Kingdom)
| |
Non-small cell lung cancer with single brain metastasis: the role of surgical treatment
M. Petrovic, N. Ilic, G. Kostic, I. Cekerevac, L. Novkovic, V. Cupurdija (Kragujevac, Serbia And Montenegro)
| |
Thoracic radiotherapy as retreatment for locally recurrent symptomatic non small cell lung cancer
N. Jovanovic Korda, S. Vucicevic, G. Gligorijevic (Belgrade, Serbia And Montenegro)
| |
A phase III randomised study comparing concomitant standard cisplatin (P) – etoposide (E) and chest irradiation to concomitant etoposide plus daily cisplatin and chest irradiation as induction therapy for limited (LD) small cell lung cancer (SCLC)
A. P. Meert, T. Berghmans, P. Van Houtte, J. J. Lafitte, A. Efremidis, M. Paesmans, N. Leclercq, M. C. Florin, J. P. Sculier (Brussels, Belgium; Lille, Douai, France; Athens, Greece)
| |
Early and late immunological effects of radio-frequency ablation in lung cancer patients
A. Cascina, F. Meloni, M. Morosini, I. Passadore, R. Dore, E. Pozzi, S. Rossi, A. M. Fietta (Pavia, Italy)
| |
Randomized phase II study of adjuvant cisplatin/docetaxel (Cis-Doc) or cisplatin/vinorelbine (Cis-VRB) in patients (pts) with resected stage IB-II NSCLC: interim analysis
P. Germonpré, P. Driesen, M. Lambrechts, L. Bosquée, F. Bustin, D. Verresen, D. Galdermans (Anwerpen, Liège, Belgium)
| |
Palliative radiotherapy and quality of life of elderly lung cancer patients
G. Gligorijevic, N. Jovanovic, Z. Milosevic (Belgrade, Serbia And Montenegro)
| |